lunes, 8 de diciembre de 2014

Familial hypercholesterolemia in Brazil: Cascade screening program,... - PubMed - NCBI

2014 Nov 14;238(1):101-107. doi: 10.1016/j.atherosclerosis.2014.11.009. [Epub ahead of print]

Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects.

Jannes CE1, Santos RD2, de Souza Silva PR3, Turolla L3, Gagliardi AC3, Marsiglia JD3, Chacra AP2, Miname MH2, Rocha VZ2, Filho WS2, Krieger JE3,Pereira AC3.

Author information

Abstract

Background: There is little knowledge about familial hypercholesterolemia in Brazil. This study presents the first results of genetic cascade screening performed in the city of Sao Paulo. Material and methods: Two-hundred and forty-eight suspected index cases were initially included. DNA was extracted from peripheral blood and the complete coding sequence of low-density lipoprotein receptor, exon 7 of proprotein convertase subtilisin/kexin type 9 gene and part of exon 26 of apolipoprotein B genes were sequenced. Multiplex Ligation-dependent Probe Amplification was performed on cases where a causal mutation was not identified through sequencing. After the identification of a causal mutation screening in first-degree relatives was pursued. Results: From 248 index cases, a mutation was found in 125 individuals (50.4%). 394 relatives were included in the cascade screening program and a mutation was identified in 59.4%. Seventy different causal mutations in the low-density lipoprotein receptor gene (97.2%) and 2 in the apolipoprotein B gene (2.8%) were found. No mutations were encountered in the proprotein convertase subtilisin/kexin type 9 gene. Mutations in exons 14 and 4 were the most prevalent and, 10 cases of true homozygotes (8 index cases and 2 relatives) and 1 compound heterozygote were identified. The most frequent mutation found was of Lebanese origin, the p.(Cys681*) mutation in exon 14 (8.5%). Conclusion: Genetic familial hypercholesterolemia cascade screening is feasible in Brazil and leads to identification of a mutation in approximately half of the index cases with higher rates of success in their relatives.